Dying mammalian cells emit numerous signals that interact with the host to dictate the
immunological correlates of cellular stress and death. In the absence of reactive antigenic�…

Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients�…

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune�…

Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only�…

Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone�…

Over the last decade, the nanomedicine has experienced unprecedented development in
diagnosis and management of diseases. A number of nanomedicines have been approved�…

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the�…

Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic
activity, have recently attracted attention as potential anticancer therapeutics. While NK cells�…

Cancer immunotherapy has significantly flourished and revolutionized the limited
conventional tumor therapies, on account of its good safety and long-term memory ability�…

The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they�…